Hospital
Cape Cod Hospital INC
Cape Cod Hospital INC was paid $86.94M by Medicaid between Jan 2018 and Dec 2024, across 488 billing codes. Its largest line is 99285, emergency room visit (most serious) — 13% of everything it billed.
33Billing provider infoCAPE COD HOSPITAL INC
HYANNIS, MA 02601
HYANNIS, MA 02601
33aNPI1114984671assigned 04/28/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$86.94M
24GClaims1,928,192
24DCodes billed488
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#17 of 66
Median peer was paid$29.11M
This provider vs. median3.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 331,258 | $14.84M | |
| 2019 | 264,764 | $11.49M | |
| 2020 | 220,047 | $8.29M | |
| 2021 | 293,001 | $11.37M | |
| 2022 | 297,575 | $13.28M | |
| 2023 | 279,934 | $14.92M | |
| 2024incomplete | 241,613 | $12.74M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 65,542 | 57,582 | $11.35M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.2% | 52,843 | 47,358 | $8.00M |
| 96361 | Intravenous infusion, hydration; each additional hour | 8.8% | 21,297 | 17,902 | $7.64M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.3% | 42,054 | 37,559 | $6.34M |
| G0378 | Hospital observation service, per hour | 3.3% | 26,102 | 10,827 | $2.89M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.3% | 24,971 | 20,570 | $2.88M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.8% | 43,011 | 37,447 | $2.43M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.7% | 15,797 | 13,938 | $2.32M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 33,881 | 10,588 | $2.09M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 12,719 | 11,976 | $1.97M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.1% | 6,432 | 5,074 | $1.84M |
| 59025 | Fetal non-stress test | 2.0% | 6,364 | 3,399 | $1.74M |
476 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 12,575 | $1.58M |
| S9485 | Crisis intervention mental health services, per diem | 1.6% | 3,020 | $1.36M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 7,711 | $1.17M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 5,244 | $960K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.1% | 12,606 | $947K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.1% | 6,906 | $917K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 19,486 | $853K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 5,366 | $828K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,360 | $783K |
| 93971 | <1% | 3,819 | $736K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 6,653 | $711K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 25,482 | $687K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,376 | $672K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,142 | $665K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 19,996 | $620K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,470 | $608K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 7,136 | $599K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 14,755 | $539K |
| 76830 | Ultrasound, transvaginal | <1% | 5,683 | $535K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,734 | $531K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 3,753 | $503K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 102,257 | $469K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 21,940 | $437K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,730 | $436K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 16,897 | $432K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,755 | $424K |
| 76642 | <1% | 5,025 | $409K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 11,285 | $406K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 15,413 | $397K |
| 96415 | <1% | 2,087 | $374K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 9,481 | $356K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 484 | $334K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,995 | $318K |
| 76801 | <1% | 3,121 | $290K | |
| J3490 | Unclassified drugs | <1% | 12,428 | $280K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 880 | $276K |
| 62323 | <1% | 602 | $269K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,637 | $260K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 997 | $245K |
| 71250 | <1% | 3,305 | $245K | |
| 93970 | <1% | 881 | $244K | |
| 76536 | <1% | 2,245 | $235K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 3,348 | $235K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,509 | $233K |
| ATP14 | <1% | 26,525 | $223K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 2,192 | $216K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12,559 | $212K |
| 64493 | <1% | 294 | $208K | |
| 72141 | <1% | 918 | $194K | |
| 93975 | <1% | 1,652 | $180K | |
| 70496 | <1% | 855 | $179K | |
| 77065 | Tomosynthesis, mammo | <1% | 2,772 | $173K |
| 97162 | <1% | 2,580 | $170K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,869 | $159K |
| 77066 | Tomosynthesis, mammo | <1% | 2,495 | $153K |
| 93017 | <1% | 1,776 | $151K | |
| 97014 | <1% | 2,903 | $149K | |
| 84484 | <1% | 22,979 | $140K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,596 | $138K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 1,572 | $136K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 377 | $134K |
| 83690 | <1% | 30,037 | $134K | |
| ATP15 | <1% | 14,998 | $133K | |
| 77412 | <1% | 610 | $132K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,363 | $131K |
| 71045 | Radiologic examination, chest; single view | <1% | 27,955 | $130K |
| 97161 | <1% | 1,795 | $130K | |
| 73630 | <1% | 4,847 | $130K | |
| ATP08 | <1% | 18,367 | $130K | |
| 72100 | <1% | 4,760 | $129K | |
| 76770 | <1% | 815 | $129K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,002 | $129K |
| 77336 | <1% | 1,616 | $122K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 871 | $121K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,243 | $118K |
| 96367 | <1% | 3,389 | $117K | |
| 80053 | Comprehensive metabolic panel | <1% | 67,781 | $116K |
| 73221 | <1% | 565 | $111K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,164 | $108K |
| 83880 | <1% | 6,175 | $108K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,890 | $106K |
| 77080 | <1% | 1,533 | $106K | |
| 74174 | <1% | 644 | $104K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 15,406 | $103K |
| 84703 | <1% | 17,276 | $99K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,216 | $98K |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | <1% | 98 | $97K |
| 94060 | <1% | 997 | $97K | |
| 83735 | <1% | 24,020 | $96K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,356 | $91K |
| 83605 | <1% | 13,688 | $90K | |
| 97035 | <1% | 2,668 | $89K | |
| 87040 | <1% | 13,931 | $89K | |
| 87430 | <1% | 7,402 | $89K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 5,544 | $88K |
| J7999 | Compounded drug, not otherwise classified | <1% | 2,502 | $86K |
| 73030 | <1% | 3,940 | $86K | |
| 90715 | <1% | 3,392 | $86K | |
| 73610 | <1% | 3,976 | $83K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 4,955 | $83K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 7,621 | $82K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 42,416 | $82K |
| 73130 | <1% | 2,875 | $81K | |
| 49083 | <1% | 178 | $75K | |
| 12001 | <1% | 368 | $74K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 183 | $73K |
| 86850 | <1% | 11,241 | $71K | |
| 73502 | <1% | 2,833 | $70K | |
| 88342 | <1% | 2,898 | $68K | |
| 73110 | <1% | 2,498 | $67K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 25,823 | $65K |
| 72040 | <1% | 1,583 | $63K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 29,754 | $62K |
| 36430 | <1% | 237 | $62K | |
| 85027 | <1% | 16,063 | $62K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 45,004 | $58K |
| 73562 | <1% | 1,953 | $57K | |
| 76813 | <1% | 451 | $56K | |
| 85610 | <1% | 22,202 | $49K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,076 | $48K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,941 | $46K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 27 | $46K |
| 86317 | <1% | 2,579 | $46K | |
| 84702 | <1% | 3,761 | $46K | |
| 87070 | <1% | 7,579 | $46K | |
| 71271 | <1% | 1,307 | $45K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 292 | $44K |
| 87077 | <1% | 8,876 | $44K | |
| 85730 | <1% | 11,113 | $44K | |
| 94729 | <1% | 898 | $44K | |
| 70498 | <1% | 958 | $44K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 198 | $42K |
| 88341 | <1% | 1,719 | $41K | |
| 70486 | <1% | 965 | $41K | |
| 73564 | <1% | 2,704 | $41K | |
| 87186 | <1% | 7,103 | $38K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 96 | $38K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,902 | $37K |
| 81001 | <1% | 19,130 | $37K | |
| 77386 | <1% | 147 | $35K | |
| 85379 | <1% | 5,051 | $34K | |
| 96368 | <1% | 1,902 | $32K | |
| 97750 | <1% | 460 | $32K | |
| 81003 | <1% | 22,027 | $32K | |
| 73140 | <1% | 930 | $30K | |
| 93880 | <1% | 380 | $30K | |
| 87081 | <1% | 5,269 | $27K | |
| 0012A | <1% | 1,414 | $27K | |
| 86618 | <1% | 2,350 | $27K | |
| 76881 | <1% | 279 | $26K | |
| 72070 | <1% | 937 | $26K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 63 | $26K |
| 12002 | <1% | 131 | $25K | |
| 94726 | <1% | 528 | $25K | |
| 82948 | <1% | 8,500 | $25K | |
| 0011A | <1% | 2,108 | $24K | |
| 77334 | <1% | 50 | $24K | |
| 86900 | <1% | 11,358 | $24K | |
| 70491 | <1% | 200 | $23K | |
| 86140 | <1% | 6,924 | $23K | |
| 81025 | <1% | 4,139 | $23K | |
| 82803 | <1% | 1,784 | $22K | |
| 86901 | <1% | 11,311 | $22K | |
| 91200 | <1% | 265 | $22K | |
| 76870 | <1% | 187 | $22K | |
| 0001A | <1% | 961 | $21K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 3,546 | $21K |
| 87632 | <1% | 147 | $21K | |
| 84439 | <1% | 3,706 | $21K | |
| 87088 | <1% | 4,001 | $20K | |
| 77085 | <1% | 438 | $20K | |
| 0002A | <1% | 731 | $20K | |
| 77280 | <1% | 82 | $20K | |
| 87476 | <1% | 916 | $20K | |
| 77062 | <1% | 919 | $20K | |
| 73080 | <1% | 1,211 | $19K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,120 | $18K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 470 | $18K |
| 77061 | <1% | 384 | $17K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 6,155 | $16K |
| 88142 | <1% | 783 | $16K | |
| 82248 | <1% | 14,457 | $16K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 112 | $16K |
| 87631 | <1% | 173 | $16K | |
| 59426 | <1% | 95 | $15K | |
| 59430 | <1% | 110 | $14K | |
| 12011 | <1% | 64 | $14K | |
| 96523 | <1% | 342 | $13K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 591 | $13K |
| 82140 | <1% | 1,775 | $13K | |
| 82728 | <1% | 2,002 | $13K | |
| 77290 | <1% | 26 | $13K | |
| 71101 | <1% | 909 | $12K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 254 | $11K |
| 74018 | <1% | 841 | $11K | |
| 73590 | <1% | 792 | $11K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,095 | $11K |
| 76981 | <1% | 134 | $10K | |
| ATP17 | <1% | 1,686 | $10K | |
| 80076 | <1% | 10,496 | $10K | |
| 76982 | <1% | 112 | $10K | |
| 85652 | <1% | 5,868 | $10K | |
| 19083 | <1% | 13 | $10K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 95 | $10K |
| 85007 | <1% | 4,410 | $10K | |
| 82607 | <1% | 1,262 | $9K | |
| 87522 | Neg quan hep c or qual rna | <1% | 294 | $9K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $9K |
| 90656 | <1% | 494 | $9K | |
| 72131 | <1% | 269 | $9K | |
| 76882 | <1% | 69 | $9K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 56 | $9K |
| 83550 | <1% | 2,117 | $9K | |
| 87210 | <1% | 2,311 | $9K | |
| 99218 | <1% | 82 | $9K | |
| 94727 | <1% | 388 | $8K | |
| 43235 | <1% | 13 | $8K | |
| ATP16 | <1% | 1,056 | $8K | |
| 94664 | <1% | 272 | $8K | |
| 90674 | <1% | 494 | $8K | |
| 80061 | Lipid panel | <1% | 4,488 | $8K |
| 74183 | <1% | 39 | $7K | |
| 87205 | <1% | 2,939 | $7K | |
| 86803 | <1% | 713 | $7K | |
| 0031A | <1% | 604 | $7K | |
| 74019 | <1% | 719 | $7K | |
| 88313 | <1% | 524 | $6K | |
| 84153 | <1% | 426 | $6K | |
| 10005 | <1% | 13 | $6K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 98 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,533 | $6K |
| 87420 | <1% | 499 | $6K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 46 | $5K |
| 20553 | <1% | 31 | $5K | |
| 87046 | <1% | 266 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,100 | $5K |
| 73090 | <1% | 333 | $5K | |
| 64494 | <1% | 207 | $5K | |
| 80050 | General health panel | <1% | 290 | $5K |
| 27096 | <1% | 13 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,531 | $5K |
| 86880 | <1% | 1,357 | $4K | |
| 83970 | <1% | 192 | $4K | |
| 87506 | <1% | 25 | $4K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,138 | $4K |
| 97166 | <1% | 55 | $4K | |
| 97012 | <1% | 91 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,298 | $4K |
| 86703 | <1% | 450 | $4K | |
| 87340 | <1% | 458 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,508 | $4K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,356 | $4K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 14 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 107 | $3K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 271 | $3K |
| 80164 | <1% | 599 | $3K | |
| 29125 | <1% | 32 | $3K | |
| 88304 | <1% | 1,746 | $3K | |
| 87536 | <1% | 100 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 228 | $3K |
| J2704 | Injection, propofol, 10 mg | <1% | 8,679 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 17,388 | $3K |
| 84481 | <1% | 271 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 18 | $3K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,913 | $3K |
| 80179 | <1% | 669 | $3K | |
| 86706 | <1% | 325 | $3K | |
| 80178 | <1% | 764 | $3K | |
| 82746 | <1% | 305 | $3K | |
| 82378 | <1% | 277 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 5,626 | $2K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 15 | $2K |
| 86704 | <1% | 229 | $2K | |
| 84402 | <1% | 117 | $2K | |
| 86708 | <1% | 242 | $2K | |
| 86308 | <1% | 531 | $2K | |
| 96417 | <1% | 964 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 38,284 | $2K |
| 86480 | <1% | 82 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,965 | $2K |
| 72146 | <1% | 27 | $2K | |
| ATP02 | <1% | 529 | $2K | |
| 83540 | <1% | 665 | $2K | |
| 82784 | <1% | 242 | $2K | |
| 86038 | <1% | 204 | $2K | |
| 82150 | <1% | 395 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,513 | $2K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 101 | $2K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 55 | $2K |
| 82652 | <1% | 101 | $2K | |
| 97163 | <1% | 39 | $2K | |
| 73552 | <1% | 294 | $2K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,254 | $2K |
| 87469 | <1% | 223 | $2K | |
| 82043 | <1% | 598 | $2K | |
| 10061 | <1% | 13 | $2K | |
| 77002 | <1% | 42 | $2K | |
| 84100 | <1% | 4,037 | $1K | |
| 84146 | <1% | 94 | $1K | |
| 20552 | <1% | 12 | $1K | |
| 86200 | <1% | 134 | $1K | |
| 0071A | <1% | 28 | $1K | |
| 82550 | <1% | 2,775 | $1K | |
| ATP09 | <1% | 238 | $1K | |
| 88173 | <1% | 13 | $1K | |
| 90686 | <1% | 143 | $1K | |
| 82105 | <1% | 92 | $1K | |
| 83001 | <1% | 84 | $1K | |
| ATP18 | <1% | 241 | $1K | |
| 87484 | <1% | 180 | $1K | |
| 87045 | <1% | 202 | $1K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 13 | $1K |
| 76775 | <1% | 13 | $1K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 61 | $1K |
| 91322 | <1% | 23 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,848 | $1K |
| 82950 | <1% | 195 | $935.58 | |
| 87324 | <1% | 144 | $927.40 | |
| 86592 | <1% | 282 | $926.25 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,598 | $918.56 |
| ATP03 | <1% | 258 | $904.70 | |
| ATP11 | <1% | 187 | $874.56 | |
| 72050 | <1% | 12 | $874.39 | |
| J7210 | Injection, factor viii, (antihemophilic factor, recombinant), (afstyla), 1 i.u. | <1% | 40 | $872.52 |
| ATP07 | <1% | 163 | $868.29 | |
| 86320 | <1% | 68 | $855.07 | |
| 73560 | <1% | 18 | $852.43 | |
| 97803 | <1% | 15 | $792.40 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 21 | $780.89 |
| 87207 | <1% | 193 | $778.94 | |
| 82009 | <1% | 313 | $774.19 | |
| 83002 | <1% | 52 | $768.54 | |
| 86696 | <1% | 46 | $733.14 | |
| 82565 | <1% | 1,967 | $720.36 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,521 | $696.24 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,117 | $695.59 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,496 | $686.60 |
| 97597 | <1% | 133 | $635.24 | |
| 36591 | <1% | 1,020 | $599.90 | |
| 73700 | <1% | 14 | $599.55 | |
| ATP04 | <1% | 130 | $580.42 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 902 | $557.84 |
| 80074 | <1% | 17 | $556.68 | |
| 84460 | <1% | 1,090 | $550.31 | |
| 73060 | <1% | 62 | $548.70 | |
| 83721 | <1% | 115 | $530.32 | |
| 86430 | <1% | 130 | $528.50 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 811 | $525.85 |
| 96376 | <1% | 7,740 | $525.43 | |
| 86361 | <1% | 87 | $521.18 | |
| 86695 | <1% | 46 | $512.49 | |
| 84165 | <1% | 83 | $498.15 | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 57 | $497.91 |
| 81002 | <1% | 381 | $468.64 | |
| 83615 | <1% | 844 | $446.28 | |
| 90480 | <1% | 36 | $441.09 | |
| 86709 | <1% | 47 | $425.94 | |
| 84450 | <1% | 1,042 | $410.73 | |
| 84134 | <1% | 59 | $406.08 | |
| 82570 | <1% | 120 | $376.42 | |
| ATP10 | <1% | 132 | $376.32 | |
| 0013A | <1% | 16 | $366.96 | |
| 86003 | <1% | 12 | $366.52 | |
| 84550 | <1% | 454 | $354.13 | |
| 94799 | <1% | 27 | $349.94 | |
| 72170 | <1% | 54 | $348.37 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 74 | $338.30 |
| 86617 | <1% | 49 | $333.95 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,108 | $333.04 |
| 84156 | <1% | 148 | $312.91 | |
| 73660 | <1% | 14 | $302.88 | |
| 85018 | <1% | 273 | $297.16 | |
| 86923 | <1% | 38 | $295.65 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 14 | $252.35 |
| 86376 | <1% | 24 | $240.16 | |
| 82962 | <1% | 4,979 | $217.80 | |
| 82553 | <1% | 44 | $207.74 | |
| 84403 | <1% | 16 | $206.34 | |
| 84520 | <1% | 770 | $206.34 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,580 | $205.60 |
| 87177 | <1% | 31 | $201.74 | |
| 82947 | <1% | 160 | $201.07 | |
| 86141 | <1% | 27 | $200.25 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 731 | $179.80 |
| 86694 | <1% | 14 | $178.08 | |
| 73000 | <1% | 13 | $172.83 | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 307 | $171.10 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 342 | $156.83 |
| 82247 | <1% | 340 | $155.34 | |
| 83516 | <1% | 22 | $153.53 | |
| 80159 | <1% | 44 | $152.56 | |
| 83655 | <1% | 13 | $149.88 | |
| 83020 | <1% | 12 | $145.97 | |
| 85014 | <1% | 155 | $127.84 | |
| 86160 | <1% | 12 | $123.80 | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 15 | $107.36 |
| 80197 | <1% | 27 | $105.28 | |
| 80156 | <1% | 20 | $105.21 | |
| 82040 | <1% | 176 | $98.78 | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 61 | $96.21 |
| 86920 | <1% | 15 | $95.48 | |
| 90694 | <1% | 48 | $82.20 | |
| 80051 | <1% | 202 | $77.63 | |
| 80177 | <1% | 14 | $68.35 | |
| 80185 | <1% | 12 | $68.35 | |
| G0008 | Administration of influenza virus vaccine | <1% | 936 | $61.60 |
| 82010 | <1% | 15 | $57.68 | |
| 84436 | <1% | 18 | $56.64 | |
| 80175 | <1% | 13 | $54.68 | |
| ATP13 | <1% | 12 | $54.45 | |
| ATP06 | <1% | 14 | $48.48 | |
| 84132 | <1% | 60 | $47.30 | |
| 82977 | <1% | 32 | $44.52 | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 325 | $42.60 |
| 88311 | <1% | 171 | $35.47 | |
| 81015 | <1% | 44 | $34.54 | |
| 85045 | <1% | 19 | $28.84 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 976 | $27.02 |
| 90899 | <1% | 61 | $25.48 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,892 | $16.90 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 677 | $13.23 |
| 90653 | <1% | 25 | $5.60 | |
| 82310 | <1% | 13 | $5.33 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 739 | $2.23 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,224 | $1.99 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 73 | $1.00 |
| 51702 | 0% | 269 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 310 | $0.00 |
| 99152 | 0% | 652 | $0.00 | |
| 91300 | 0% | 1,047 | $0.00 | |
| G0176 | Activity therapy, such as music, dance, art or play therapies not for recreation, related to the care and treatment of patient's disabling mental health problems, per session (45 minutes or more) | 0% | 1,136 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 465 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 301 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 608 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 58 | $0.00 |
| G0177 | Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) | 0% | 1,142 | $0.00 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 72 | $0.00 |
| G0129 | Occupational therapy services requiring the skills of a qualified occupational therapist, furnished as a component of a partial hospitalization or intensive outpatient treatment program, per session (45 minutes or more) | 0% | 1,268 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 230 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 260 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 19 | $0.00 |
| 51701 | 0% | 193 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 13 | $0.00 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | 0% | 48 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 236 | $0.00 |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 0% | 72 | $0.00 |
| 77387 | 0% | 63 | $0.00 | |
| 84145 | 0% | 14 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 13 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 650 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 470 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 28 | $0.00 |
| 96411 | 0% | 39 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 319 | $0.00 |
| C1769 | Guide wire | 0% | 816 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 316 | $0.00 |
| 87493 | 0% | 39 | $0.00 | |
| J8501 | Aprepitant, oral, 5 mg | 0% | 439 | $0.00 |
| 94760 | 0% | 505 | $0.00 | |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | 0% | 920 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 248 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 1,563 | $0.00 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 171 | $0.00 |
| 91301 | 0% | 1,916 | $0.00 | |
| 80069 | 0% | 28 | $0.00 | |
| 0346T | 0% | 134 | $0.00 | |
| 91303 | 0% | 332 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 68 | $0.00 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 0% | 100 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 101 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 149 | $0.00 |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 0% | 250 | $0.00 |
| 80320 | 0% | 174 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 19 | $0.00 |
| 88300 | 0% | 12 | $0.00 | |
| J3535 | Drug administered through a metered dose inhaler | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAYTON, REBECCA (VP OF REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| Falmouth Hospital Association INC | Falmouth, MA | $25.40M |
| Medical Affiliates of Cape Cod, INC. | Hyannis, MA | $5.91M |
| Urgi Center Medical Group | Sandwich, MA | $5.85M |
| Physicians of Cape Cod Hospital | Hyannis, MA | $5.21M |
| Emergency Physicians of Falmouth | Falmouth, MA | $2.69M |
| Physicians of Falmouth Hospital | Falmouth, MA | $346K |
| Cape Cod Hospital INC | Hyannis, MA | $291K |
| Radiologists of Cape Cod Hospital | Hyannis, MA | $51K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.